• Danzon P. 1997. Price discrimination for pharmaceuticals: welfare effects in the US and EU. International Journal Economics Business 4(3): 301321.
  • Danzon PM, Chao L-W. 2000a. Cross-national price differences for pharmaceuticals: how large and why? Journal of Health Economics 19: 159195.
  • Danzon P, Chao L-W. 2000b. Does regulation drive out competition in markets for pharmaceuticals? Journal of Law and Economics 43: 311358.
  • Danzon P, Epstein A. 2009. Effects of Regulation on Drug Launch and Pricing in Interdependent Markets. NBER Working Paper 14041.
  • Danzon P, Furukawa M. 2008. International prices and availability of pharmaceuticals in 2005. Health Affairs 27(1): 221233.
  • Danzon P, Furukawa M. 2011. Cross-national Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-driven Markets. NBERWorking Paper 17226.
  • Danzon, P, Towse A. 2003. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. International Journal Health Care Finance and Econ 3: 183205.
  • Danzon P et al. 2012. Value-based differential pricing: Efficient prices for drugs in a global context. NBER Working Paper 18593.
  • Danzon P, Wang Y, Wang L. 2012. The impact of price regulation on the launch delay of new drugs: a study of twenty-five major markets in 1990s. Health Economics 14(3): 269292.
  • Flynn A et al. 2009. An economic justification for open access to essential medicine patents in developing countries. Journal of Law, Medicine, and Ethics Summer: 2009: 184208.
  • Frank RG, Salkever DS. 1997. Generic entry and pricing of pharmaceuticals. Journal of Economics and Management Strategy 6(1): 7590.
  • Hall, RE, Jones CI. 2007. The value of life and the rise in health spending. QJE 122(1): 3972.
  • Jack W, Lanjouw, JO. 2005. Financing pharmaceutical innovation: how much should poor countries contribute? The World Bank Economic Review 19(1): 4567.
  • Kapstein E, Busby J. 2009. Making markets for merit goods: the political economy of antiretrovirals. Center for Global Development Working Paper 179.
  • Kennedy PE. 1981. Estimation with correctly interpreted dummy variables in semilogarithmic equations. AER
  • Malueg D, Schwartz M. 1994. Parallel imports, demand dispersion, and international price discrimination. Journal of International Economics 37: 167195.
  • Maskus KE. 2001. Parallel Imports in Pharmaceuticals: Implications for Competition and Prices in Developing Countries. Final Report to World Intellectual Property Organization.
  • Scherer FM, Watel J. 2001. Post-Trips Options for Access to Patented Medicines in Developing Countries. CMH Working Paper Series, Paper No. WG4: 1. Available at:
  • Szymanski, S, Valletti, T. 2005. Parallel trade, price discrimination, investment and price caps. Economic Policy 20(44): 705749.
    Direct Link:
  • Valletti TM, Szymanski S. 2006. Parallel trade, international exhaustion and intellectual property rights: a welfare analysis. The Journal of Industrial Economics 54(4): 499526.
  • Waning B et al. 2009. Global strategies to reduce the price of anti-retroviral medicines: evidence from transactional databases. Bulletin of the World Health Organization 87(7).